BUCILLAMINE (A NEW THERAPEUTIC AGENT FOR RHEUMATOID-ARTHRITIS) INDUCED NEPHROTIC SYNDROME - A REPORT OF 2 CASES AND REVIEW OF THE LITERATURE

T ISOZAKI; M KIMURA; N IKEGAYA; T ARAI; Y FUJIGAKI; A HISHIDA; E KANEKO

BUCILLAMINE (A NEW THERAPEUTIC AGENT FOR RHEUMATOID-ARTHRITIS) INDUCED NEPHROTIC SYNDROME - A REPORT OF 2 CASES AND REVIEW OF THE LITERATURE

T ISOZAKI
, M KIMURA
, N IKEGAYA
, T ARAI
, Y FUJIGAKI
, A HISHIDA
, E KANEKO

School of Medicine

Research output: Contribution to journal › Article

Abstract

Two cases of nephrotic syndrome during bucillamine treatment were encountered in 1989 in our hospital; both patients had suffered from rheumatoid arthritis for 2 years. They had received 200 mg bucillamine orally per day for 3-4 months before the onset of the nephrotic syndrome. Discontinuation of bucillamine led to complete remission of the nephrotic syndrome within 1 year. Bucillamine is a new therapeutic agent for rheumatoid arthritis developed in 1982 in Japan. Since 1985, 14 cases of nephrotic syndrome, including the two cases reported here have been reported. We review these cases and discuss the pathogenesis.

Original language	English
Pages (from-to)	1036-1042
Number of pages	7
Journal	Clinical Investigator
Volume	70
Issue number	11
State	Published - Nov 1992

Cite this

@article{fc8391db96674cf2bd1a90bd87493b7c,

title = "BUCILLAMINE (A NEW THERAPEUTIC AGENT FOR RHEUMATOID-ARTHRITIS) INDUCED NEPHROTIC SYNDROME - A REPORT OF 2 CASES AND REVIEW OF THE LITERATURE",

abstract = "Two cases of nephrotic syndrome during bucillamine treatment were encountered in 1989 in our hospital; both patients had suffered from rheumatoid arthritis for 2 years. They had received 200 mg bucillamine orally per day for 3-4 months before the onset of the nephrotic syndrome. Discontinuation of bucillamine led to complete remission of the nephrotic syndrome within 1 year. Bucillamine is a new therapeutic agent for rheumatoid arthritis developed in 1982 in Japan. Since 1985, 14 cases of nephrotic syndrome, including the two cases reported here have been reported. We review these cases and discuss the pathogenesis.",

author = "T ISOZAKI and M KIMURA and N IKEGAYA and T ARAI and Y FUJIGAKI and A HISHIDA and E KANEKO",

year = "1992",

month = nov,

language = "英語",

volume = "70",

pages = "1036--1042",

journal = "Clinical Investigator",

issn = "0941-0198",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "11",

}

TY - JOUR

T1 - BUCILLAMINE (A NEW THERAPEUTIC AGENT FOR RHEUMATOID-ARTHRITIS) INDUCED NEPHROTIC SYNDROME - A REPORT OF 2 CASES AND REVIEW OF THE LITERATURE

AU - ISOZAKI, T

AU - KIMURA, M

AU - IKEGAYA, N

AU - ARAI, T

AU - FUJIGAKI, Y

AU - HISHIDA, A

AU - KANEKO, E

PY - 1992/11

Y1 - 1992/11

N2 - Two cases of nephrotic syndrome during bucillamine treatment were encountered in 1989 in our hospital; both patients had suffered from rheumatoid arthritis for 2 years. They had received 200 mg bucillamine orally per day for 3-4 months before the onset of the nephrotic syndrome. Discontinuation of bucillamine led to complete remission of the nephrotic syndrome within 1 year. Bucillamine is a new therapeutic agent for rheumatoid arthritis developed in 1982 in Japan. Since 1985, 14 cases of nephrotic syndrome, including the two cases reported here have been reported. We review these cases and discuss the pathogenesis.

AB - Two cases of nephrotic syndrome during bucillamine treatment were encountered in 1989 in our hospital; both patients had suffered from rheumatoid arthritis for 2 years. They had received 200 mg bucillamine orally per day for 3-4 months before the onset of the nephrotic syndrome. Discontinuation of bucillamine led to complete remission of the nephrotic syndrome within 1 year. Bucillamine is a new therapeutic agent for rheumatoid arthritis developed in 1982 in Japan. Since 1985, 14 cases of nephrotic syndrome, including the two cases reported here have been reported. We review these cases and discuss the pathogenesis.

M3 - 記事

SN - 0941-0198

VL - 70

SP - 1036

EP - 1042

JO - Clinical Investigator

JF - Clinical Investigator

IS - 11

ER -

BUCILLAMINE (A NEW THERAPEUTIC AGENT FOR RHEUMATOID-ARTHRITIS) INDUCED NEPHROTIC SYNDROME - A REPORT OF 2 CASES AND REVIEW OF THE LITERATURE

Abstract

Fingerprint

Cite this